134 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28274635	381	Identification of novel TACE inhibitors compatible with topical application.	Nestl�
28151653	35	Full Sequence Amino Acid Scanning of¿-Defensin RTD-1 Yields a Potent Anthrax Lethal Factor Protease Inhibitor.	State University of New York
27966948	86	Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach.	Pharmaceutical
27825552	152	Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.	Takeda Pharmaceutical
26871660	68	Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models.	San Raffaele Scientific Institute
26653735	81	Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.	Pfizer
26753813	22	Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid.	University of Minnesota
26638045	58	Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors.	Uit The Arctic University of Norway
26288689	37	Discovery of Potent and Selective Inhibitors for ADAMTS-4 through DNA-Encoded Library Technology (ELT).	Glaxosmithkline
26192023	71	SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.	Florida Atlantic University
25264600	64	Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.	Takeda Pharmaceutical
25415648	63	Identification of potent and selective hydantoin inhibitors of aggrecanase-1 and aggrecanase-2 that are efficacious in both chemical and surgical models of osteoarthritis.	Eli Lilly
25192810	66	Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1¿ binding site.	Takeda Pharmaceutical
24735644	19	Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-ß hydrolysis.	University of Lille
24316668	34	Discovery of a benzimidazole series of ADAMTS-5 (aggrecanase-2) inhibitors by scaffold hopping.	Asahi Kasei Pharma
24044937	59	Aggrecanase-2 inhibitors based on the acylthiosemicarbazide zinc-binding group.	University of Lille
24044434	71	Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models.	UniversitÀ
23453070	42	A series of thiazole derivatives bearing thiazolidin-4-one as non-competitive ADAMTS-5 (aggrecanase-2) inhibitors.	Asahi Kasei Pharma
22891645	83	Discovery of highly potent and selective small molecule ADAMTS-5 inhibitors that inhibit human cartilage degradation via encoded library technology (ELT).	Glaxosmithkline
22175799	22	Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis.	Alantos Pharmaceuticals
19715320	87	Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.	University of Florida
19095454	63	Current perspective of TACE inhibitors: a review.	The M. S. University of Baroda
18257543	16	Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis.	The Hebrew University of Jerusalem
12773042	195	Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.	Wyeth Research
12773041	119	Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.	Wyeth Research
11831904	172	New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.	Nippon Organon K.K.
11472217	157	Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.	Dupont Pharmaceuticals
10669559	180	Protease inhibitors: current status and future prospects.	University of Queensland
11677139	92	The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.	Wyeth-Ayerst Research
11206468	24	Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.	Wyeth-Ayerst Research
11206467	44	The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.	Wyeth-Ayerst Research
11514167	88	The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.	Wyeth-Ayerst Research
22175825	19	Potent inhibitors of LpxC for the treatment of Gram-negative infections.	Pfizer
22017477	35	Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases.	Instituto Superior T£Cnico
21963348	7	Synthesis, preliminary biological evaluation and molecular modeling of some new heterocyclic inhibitors of TACE.	Sun Pharma Advanced Research
20638281	56	Structure and activity relationships of tartrate-based TACE inhibitors.	Merck Research Laboratories
21458257	87	2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.	Merck Research Laboratories
21417219	179	Discovery of (1S,2R,3R)-2,3-dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: novel and highly selective aggrecanase inhibitors.	Central Pharmaceutical Research Institute
21300546	129	The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis.	Astrazeneca
21078557	34	Structure based optimization of chromen-based TNF-a converting enzyme (TACE) inhibitors on S1' pocket and their quantitative structure-activity relationship (QSAR) study.	Yonsei University
21106451	39	Novel TNF-a converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases.	Merck Research Laboratories
20663669	36	Biaryl substituted hydantoin compounds as TACE inhibitors.	Merck Research Laboratories
20180536	128	Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.	Universit£
20172725	49	Discovery and SAR of hydantoin TACE inhibitors.	Merck Research Laboratories
19767207	17	Synthesis and SAR of 2-phenyl-1-sulfonylaminocyclopropane carboxylates as ADAMTS-5 (Aggrecanase-2) inhibitors.	Central Pharmaceutical Research Institute
20022498	71	The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors.	Schering-Plough Research Institute
20005097	58	Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.	Pfizer
19908842	84	Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB.	National Human Genome Research Institute
19703773	63	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors.	Gsk Medicines Research Centre
19725580	93	Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.	Wyeth Research
19606871	124	N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.	Universit£
18835710	69	Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.	Schering-Plough Research Institute
19410464	71	Synthesis and activity of tryptophan sulfonamide derivatives as novel non-hydroxamate TNF-alpha converting enzyme (TACE) inhibitors.	Wyeth Research
19053764	101	Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates.	Instituto Superior TéCnico
18790648	317	Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.	University of Athens
17936631	25	Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation.	Yonsei University
17531482	67	Design and synthesis of 3,3-piperidine hydroxamate analogs as selective TACE inhibitors.	Wyeth Research
17368021	55	Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Bristol-Myers Squibb Pharmaceutical Research Institute
17276676	112	A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
17064892	123	Identification of potent and selective TACE inhibitors via the S1 pocket.	Wyeth Research
16723229	108	Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.	Wyeth Research
16516469	39	A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors.	Novartis Institutes For Biomedical Research
16516466	175	Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
16473009	23	Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
16426848	80	Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates.	Wyeth Research
16289878	35	Conversion of potent MMP inhibitors into selective TACE inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
16153831	87	Synthesis and SAR of highly selective MMP-13 inhibitors.	Wyeth Research
16084720	83	Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.	Wyeth Research
15953722	56	Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.	Pfizer
15911259	49	Discovery of 3,3-dimethyl-5-hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP-13.	Pfizer
15908214	95	Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.	Bristol-Myers Squibb Pharmaceutical Research Institute
15745814	75	Synthesis and SAR of diazepine and thiazepine TACE and MMP inhibitors.	Wyeth Research
15686921	55	Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).	Pharmaceutical Research Institute
15566296	142	Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.	Wyeth Research
15546732	11	Structure-based virtual screening and biological evaluation of potent and selective ADAM12 inhibitors.	Department of Life Science and National Research Laboratory of Proteolysis
15357971	228	Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
15261259	48	Benzodiazepine inhibitors of the MMPs and TACE. Part 2.	Wyeth Research
15125955	84	Reverse hydroxamate-based selective TACE inhibitors.	Kaken Pharmaceutical
15055993	30	Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents.	Hokkaido Collaboration Center N-21
15006405	20	Synthesis and biological activity of selective azasugar-based TACE inhibitors.	Organon K.K.
12951101	79	Synthesis and biological activity of piperazine-based dual MMP-13 and TNF-alpha converting enzyme inhibitors.	Pfizer
12877590	28	A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.	Pfizer
12873518	81	Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.	Wyeth Research
12873505	20	Design, synthesis and evaluation of novel azasugar-based MMP/ADAM inhibitors.	Hokkaido Collaboration Center
12873504	36	Structure--activity relationships of azasugar-based MMP/ADAM inhibitors.	Hokkaido Collaboration Center
12781190	113	Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Bristol-Myers Squibb Pharmaceutical Research Institute
12781187	15	Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Organon K.K.
12723945	167	Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
12668018	138	Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.	Wyeth-Ayerst Research
12408705	73	Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.	Bristol-Myers Squibb
12270165	80	Benzodiazepine inhibitors of the MMPs and TACE.	Wyeth Research
11992783	78	Synthesis and biological activity of selective pipecolic acid-based TNF-alpha converting enzyme (TACE) inhibitors.	Pfizer
11934588	69	Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.	Wyeth-Ayerst Research
11831905	33	New strategy for antedrug application: development of metalloproteinase inhibitors as antipsoriatic drugs.	Organon K.K.
11708926	84	Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Glaxosmithkline
11677124	67	Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-alpha converting enzyme.	Abbott Laboratories
11514157	48	N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.	Glaxosmithkline
32470298	42	-Aryl-3-mercaptosuccinimides as Antivirulence Agents Targeting	Helmholtz Institute For Pharmaceutical Research Saarland (Hips) - Helmholtz Centre For Infection Research (Hzi
27045975	34	Notch Antagonists: Potential Modulators of Cancer and Inflammatory Diseases.	Centre Hospitalier Universitaire Vaudois (Chuv)
27194201	164	Use of Osmotic Pumps to Establish the Pharmacokinetic-Pharmacodynamic Relationship and Define Desirable Human Performance Characteristics for Aggrecanase Inhibitors.	Eli Lilly
10579851	151	New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors.	Astrazeneca
12014967	25	Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme.	Preclinical Research Novartis Pharma
28818461	67	Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis.	Nestl�
30034605	15	In Search of Selectivity in Inhibition of ADAM10.	University of Notre Dame
28711352	14	Development of a prodrug of hydantoin based TACE inhibitor.	Merck
28122457	12	Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets.	Taipei Medical University
28558971	38	Fused bi-heteroaryl substituted hydantoin compounds as TACE inhibitors.	Merck
28408220	55	First insight into structure-activity relationships of selective meprin? inhibitors.	Fraunhofer Institute For Cell Therapy and Immunology Izi
16206837	9	Tyrosinase inhibition: conformational analysis based studies on molecular dynamics calculations of bipiperidine based inhibitors.	University of Karachi
9353361	3	[3H]RY 80: A high-affinity, selective ligand for gamma-aminobutyric acidA receptors containing alpha-5 subunits.	National Institute of Diabetes and Digestive and Kidney Diseases
7515823	54	Actions of phenylglycine analogs at subtypes of the metabotropic glutamate receptor family.	Novo Nordisk
7509389	8	Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.	Fujisawa Pharmaceutical
7473144	1	Pharmacological characterization of GT-2016, a non-thiourea-containing histamine H3 receptor antagonist: in vitro and in vivo studies.	Gliatech
18355729	12	Structure-based dissection of the natural product cyclopentapeptide chitinase inhibitor argifin.	University of Dundee